Psychoneuroimmune Implications of Type 2 Diabetes

Neurologic Clinics

Volumn 24, Issue 3, 2006, Pages 539-559

  O'Connor, Jason C ^a   Johnson, Daniel R ^a   Freund, Gregory G ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; I KAPPA B KINASE BETA; INSULIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; CHRONIC INFLAMMATION; COMORBIDITY; CYTOLOGY; DISEASE ASSOCIATION; DISEASE EXACERBATION; EMOTION; FEVER; HUMAN; HUMORAL IMMUNITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; IMMUNE RESPONSE; IMMUNE STATUS; INFLAMMATORY DISEASE; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; NEUROIMMUNOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; STROKE; WELLBEING; WOUND HEALING;

ACUTE-PHASE PROTEINS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CYTOKINES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCOCORTICOIDS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNITY, NATURAL; INFLAMMATION; INSULIN RESISTANCE; LIPOPOLYSACCHARIDES; MICE; PSYCHONEUROIMMUNOLOGY; RATS; SICK ROLE;

EID: 33746319372     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2006.03.001     Document Type: Review

References (143)

1. American Diabetes Association. Diabetes facts and figures (2003), American Diabetes Association, Alexandria(VA)
2. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
3. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabetic Med 21 (2004) 203-207
4. Sherwin R. Diabetes mellitus. In: Bennet J., and Plum F. (Eds). Cecil textbook of medicine (1996), WB Saunders, Philadelphia 1258-1277
5. Crawford J.M., and Cotran R.S. The Pancreas. In: Collins T., Kuma K., and Cotran K.S. (Eds). Robbins pathologic basis of disease (1999), W.B. Saunders, Philadelphia 915-929
6. Zimmet P.Z., and Alberti K.G. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet 350 Suppl 1 (1997) SI1-SI4
7. Harris M., and Zimmet P. International textbook of diabetes mellitus. In: Alberti K., Zimmet P., and DeFronzo R. (Eds) (1999), Wiley, Chichester(England) 9-23
8. Spranger J., Kroke A., Mohlig M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52 (2003) 812-817
9. Zimmet P.Z. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 42 (1999) 499-518
10. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?. J Intern Med 247 (2000) 301-310
11. Kitagawa T., Owada M., Urakami T., et al. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 37 (1998) 111-115
12. Muller L.M., Gorter K.J., Hak E., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41 (2005) 281-288
13. Mastropaolo M.D., Evans N.P., Byrnes M.K., et al. Synergy in polymicrobial infections in a mouse model of type 2 diabetes. Infect Immun 73 (2005) 6055-6063
14. Taylor S.I. Deconstructing type 2 diabetes. Cell 97 (1999) 9-12
15. Bertoni A.G., Saydah S., and Brancati F.L. Diabetes and the risk of infection-related mortality in the US. Diabetes Care 24 (2001) 1044-1049
16. Shah B.R., and Hux J.E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26 (2003) 510-513
17. Llorente L., De La Fuente H., Richaud-Patin Y., et al. Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology. Immunol Lett 74 (2000) 239-244
18. Geerlings S.E., and Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26 (1999) 259-265
19. Taubes G. Neuroscience. Insulin insults may spur Alzheimer's disease. Science 301 (2003) 40-41
20. Kernan W.N., Inzucchi S.E., Viscoli C.M., et al. Insulin resistance and risk for stroke. Neurology 59 (2002) 809-815
21. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004) 813-823
22. Maddigan S.L., Feeny D.H., and Johnson J.A. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 14 (2005) 1311-1320
23. Maddigan S.L., Feeny D.H., and Johnson J.A. A comparison of the health utilities indices Mark 2 and Mark 3 in type 2 diabetes. Med Decis Making 23 (2003) 489-501
24. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
25. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003) 1785-1788
26. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112 (2003) 1821-1830
27. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
28. Duncan B.B., Schmidt M.I., Pankow J.S., et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52 (2003) 1799-1805
29. Freeman D.J., Norrie J., Caslake M.J., et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51 (2002) 1596-1600
30. Krein S.L., Vijan S., Pogach L.M., et al. Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care 25 (2002) 965-970
31. Arkan M.C., Hevener A.L., Greten F.R., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11 (2005) 191-198
32. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11 (2005) 183-190
33. Baron S.H. Salicylates as hypoglycemic agents. Diabetes Care 5 (1982) 64-71
34. White M.F. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283 (2002) E413-E422
35. Hotamisligil G.S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996) 665-668
36. Kanety H., Feinstein R., Papa M.Z., et al. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 270 (1995) 23780-23784
37. Pradhan A.D., Manson J.E., Rifai N., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
38. Festa A., D'Agostino Jr. R., Tracy R.P., et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51 (2002) 1131-1137
39. Welham M.J., Bone H., Levings M., et al. Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells. J Biol Chem 272 (1997) 1377-1381
40. Peraldi P., Hotamisligil G.S., Buurman W.A., et al. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 271 (1996) 13018-13022
41. Klover P.J., Zimmers T.A., Koniaris L.G., et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52 (2003) 2784-2789
42. Mooney R.A., Senn J., Cameron S., et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276 (2001) 25889-25893
43. Senn J.J., Klover P.J., Nowak I.A., et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 (2002) 3391-3399
44. Senn J.J., Klover P.J., Nowak I.A., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278 (2003) 13740-13746
45. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
46. Esposito K., Nappo F., Marfella R., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106 (2002) 2067-2072
47. Krogh-Madsen R., Plomgaard P., Keller P., et al. Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 286 (2004) E234-E238
48. Bluher M., Fasshauer M., Tonjes A., et al. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 113 (2005) 534-537
49. O'Connor J.C., Satpathy A., Hartman M.E., et al. IL-1beta-mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes. J Immunol 174 (2005) 4991-4997
50. Pickup J.C., Day C., Bailey C.J., et al. Plasma sialic acid in animal models of diabetes mellitus: evidence for modulation of sialic acid concentrations by insulin deficiency. Life Sci 57 (1995) 1383-1391
51. Lin Y., Rajala M.W., Berger J.P., et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 276 (2001) 42077-42083
52. Ebeling P., Teppo A.M., Koistinen H.A., et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia 42 (1999) 1433-1438
53. Scott C.L. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 92 1A (2003) 35i-42i
54. Hartman M.E., O'Connor J.C., Godbout J.P., et al. Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus. J Biol Chem 279 (2004) 28045-28050
55. Aronson D., and Rayfield E.J. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 1 (2002) 1
56. Hill J.R., Kwon G., Marshall C.A., et al. Hyperglycemic levels of glucose inhibit interleukin 1 release from RAW 264.7 murine macrophages by activation of protein kinase C. J Biol Chem 273 (1998) 3308-3313
57. Iida K.T., Suzuki H., Sone H., et al. Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase-dependent pathway. Arterioscler Thromb Vasc Biol 22 (2002) 380-386
58. Ceolotto G., Gallo A., Miola M., et al. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 48 (1999) 1316-1322
59. Iida K.T., Shimano H., Kawakami Y., et al. Insulin up-regulates tumor necrosis factor-alpha production in macrophages through an extracellular-regulated kinase-dependent pathway. J Biol Chem 276 (2001) 32531-32537
60. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 500 (2004) 399-411
61. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108 (2003) 2317-2322
62. Yaffe K., Lindquist K., Penninx B.W., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61 (2003) 76-80
63. Penninx B.W., Kritchevsky S.B., Yaffe K., et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry 54 (2003) 566-572
64. Sluzewska A., Rybakowski J., Bosmans E., et al. Indicators of immune activation in major depression. Psychiatry Res 64 (1996) 161-167
65. Kluger M., Kozak W., and Mayfield K. Fever and immunity. In: Ader R., Felton D., and Cohen N. (Eds). Psychoneuroimmunology (2001), Academic Press, San Diego 687-702
66. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav Immun 15 (2001) 7-24
67. Turrin N.P., and Plata-Salaman C.R. Cytokine-cytokine interactions and the brain. Brain Res Bull 51 (2000) 3-9
68. Cartmell T., Poole S., Turnbull A.V., et al. Circulating interleukin-6 mediates the febrile response to localised inflammation in rats. J Physiol 526 Pt 3 (2000) 653-661
69. Luheshi G.N., Stefferl A., Turnbull A.V., et al. Febrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF-alpha in the rat. Am J Physiol 272 3 Pt 2 (1997) R862-R868
70. Nadeau S., and Rivest S. Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor kappa B activity in the brain during endotoxemia. J Neurosci 20 (2000) 3456-3468
71. Mathison J.C., Ulevitch R.J., Fletcher J.R., et al. The distribution of lipopolysaccharide in normocomplementemic and C3-depleted rabbits and rhesus monkeys. Am J Pathol 101 (1980) 245-263
72. Fox E.S., Broitman S.A., and Thomas P. Bacterial endotoxins and the liver. Lab Invest 63 (1990) 733-741
73. Braude A.I., Carey F.J., and Zalesky M. Studies with radioactive endotoxin. II. Correlation of physiologic effects with distribution of radioactivity in rabbits injected with radioactive sodium chromate. J Clin Invest 34 (1955) 858-866
74. Armbrust T., and Ramadori G. Functional characterization of two different Kupffer cell populations of normal rat liver. J Hepatol 25 (1996) 518-528
75. Bioulac-Sage P., Kuiper J., Van Berkel T.J., et al. Lymphocyte and macrophage populations in the liver. Hepatogastroenterology 43 (1996) 4-14
76. Li Z., and Blatteis C.M. Fever onset is linked to the appearance of lipopolysaccharide in the liver. J Endotoxin Res 10 (2004) 39-53
77. Plata-Salaman C.R., Peloso E., and Satinoff E. Cytokine-induced fever in obese (fa/fa) and lean (Fa/Fa) Zucker rats. Am J Physiol 275 4 Pt 2 (1998) R1353-R1357
78. Ivanov A.I., Kulchitsky V.A., and Romanovsky A.A. Does obesity affect febrile responsiveness?. Int J Obes Relat Metab Disord 25 (2001) 586-589
79. Ivanov A.I., and Romanovsky A.A. Fever responses of Zucker rats with and without fatty mutation of the leptin receptor. Am J Physiol Regul Integr Comp Physiol 282 (2002) R311-R316
80. Dantzer R., Bluthe R., Castanon N., et al. Cytokine effects on behavior. In: Ader R., Felton D., and Cohen N. (Eds). Psychoneuroimmunology (2001), Academic Press, San Diego 703-727
81. Dantzer R., Bluthe R.M., Gheusi G., et al. Molecular basis of sickness behavior. Ann N Y Acad Sci 856 (1998) 132-138
82. Dunn A.J., and Swiergiel A.H. The role of cytokines in infection-related behavior. Ann N Y Acad Sci 840 (1998) 577-585
83. Aubert A. Sickness and behaviour in animals: a motivational perspective. Neurosci Biobehav Rev 23 (1999) 1029-1036
84. Hart B.L. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12 (1988) 123-137
85. Yirmiya R., Pollak Y., Morag M., et al. Illness, cytokines, and depression. Ann N Y Acad Sci 917 (2000) 478-487
86. Yirmiya R. Depression in medical illness: the role of the immune system. West J Med 173 (2000) 333-336
87. Konsman J.P., Parnet P., and Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25 (2002) 154-159
88. Burgess W., Gheusi G., Yao J., et al. Interleukin-1beta-converting enzyme-deficient mice resist central but not systemic endotoxin-induced anorexia. Am J Physiol 274 6 Pt 2 (1998) R1829-R1833
89. Bluthe R.M., Dantzer R., and Kelley K.W. Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology 22 (1997) 1-11
90. Swiergiel A.H., and Dunn A.J. The roles of IL-1, IL-6, and TNFalpha in the feeding responses to endotoxin and influenza virus infection in mice. Brain Behav Immun 13 (1999) 252-265
91. Schiepers O.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 201-217
92. Ciechanowski P.S., Katon W.J., Russo J.E., et al. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 25 (2003) 246-252
93. McKellar J.D., Humphreys K., and Piette J.D. Depression increases diabetes symptoms by complicating patients' self-care adherence. Diabetes Educ 30 (2004) 485-492
94. Romanovsky A.A., Ivanov A.I., Lenczowski M.J., et al. Lipopolysaccharide transport from the peritoneal cavity to the blood: is it controlled by the vagus nerve?. Auton Neurosci 85 (2000) 133-140
95. Bluthe R.M., Castanon N., Pousset F., et al. Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats. Psychoneuroendocrinology 24 (1999) 301-311
96. Plata-Salaman C.R., Vasselli J.R., and Sonti G. Differential responsiveness of obese (fa/fa) and lean (Fa/Fa) Zucker rats to cytokine-induced anorexia. Obes Res 5 (1997) 36-42
97. Naguib G., Al-Mashat H., Desta T., et al. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol 123 (2004) 87-92
98. Bluthe R.M., Lestage J., Rees G., et al. Dual effect of central injection of recombinant rat interleukin-4 on lipopolysaccharide-induced sickness behavior in rats. Neuropsychopharmacology 26 (2002) 86-93
99. Bluthe R., Kelley K., and Dantzer R. Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice. Brain Behav Immun 20 1 (2006) 57-63
100. Johnson D.R., O'Connor J.C., Dantzer R., et al. Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness. Proc Natl Acad Sci U S A 102 (2005) 15184-15189
101. Gabay C., Porter B., Guenette D., et al. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. Blood 93 (1999) 1299-1307
102. Ohmori Y., Smith Jr. M.F., and Hamilton T.A. IL-4-induced expression of the IL-1 receptor antagonist gene is mediated by STAT6. J Immunol 157 (1996) 2058-2065
103. Pousset F., Cremona S., Dantzer R., et al. IL-10 and IL-4 regulate type-I and type-II IL-1 receptors expression on IL-1 beta-activated mouse primary astrocytes. J Neurochem 79 (2001) 726-736
104. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 18 (2004) 407-413
105. Banks W.A., Farr S.A., and Morley J.E. Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation 10 (2002) 319-327
106. Bluthe R.M., Michaud B., Kelley K.W., et al. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport 7 (1996) 2823-2827
107. Wieczorek M., Swiergiel A.H., Pournajafi-Nazarloo H., et al. Physiological and behavioral responses to interleukin-1beta and LPS in vagotomized mice. Physiol Behav 85 (2005) 500-511
108. Watkins L.R., Maier S.F., and Goehler L.E. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci 57 (1995) 1011-1026
109. Banks W.A., and Kastin A.J. Relative contributions of peripheral and central sources to levels of IL-1 alpha in the cerebral cortex of mice: assessment with species-specific enzyme immunoassays. J Neuroimmunol 79 (1997) 22-28
110. Banks W.A., Ortiz L., Plotkin S.R., et al. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 259 (1991) 988-996
111. Breder C.D., Hazuka C., Ghayur T., et al. Regional induction of tumor necrosis factor alpha expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci U S A 91 (1994) 11393-11397
112. Sternberg E.M. Neural-immune interactions in health and disease. J Clin Invest 100 (1997) 2641-2647
113. Woiciechowsky C., Asadullah K., Nestler D., et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 4 (1998) 808-813
114. Banks W.A. The source of cerebral insulin. Eur J Pharmacol 490 (2004) 5-12
115. Starr J.M., Wardlaw J., Ferguson K., et al. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 74 (2003) 70-76
116. Mooradian A.D., Haas M.J., Batejko O., et al. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 54 (2005) 2977-2982
117. Duckrow R.B., Beard D.C., and Brennan R.W. Regional cerebral blood flow decreases during chronic and acute hyperglycemia. Stroke 18 (1987) 52-58
118. Fogelstrand L., Hulthe J., Hulten L.M., et al. Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance. Diabetologia 47 (2004) 1948-1952
119. Cipolletta C., Ryan K.E., Hanna E.V., et al. Activation of peripheral blood CD14 + monocytes occurs in diabetes. Diabetes 54 (2005) 2779-2786
120. O'Rourke L., Gronning L.M., Yeaman S.J., et al. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 277 (2002) 42557-42562
121. Stoffels K., Overbergh L., Giulietti A., et al. NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. J Autoimmun 23 (2004) 9-15
122. Wang J.Y., Yang J.M., Tao P.L., et al. Synergistic apoptosis induced by bacterial endotoxin lipopolysaccharide and high glucose in rat microglia. Neurosci Lett 304 (2001) 177-180
123. Zykova S.N., Jenssen T.G., Berdal M., et al. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 49 (2000) 1451-1458
124. Barber A.J., Antonetti D.A., Kern T.S., et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 46 (2005) 2210-2218
125. Zhang L., Nair A., Krady K., et al. Estrogen stimulates microglia and brain recovery from hypoxia-ischemia in normoglycemic but not diabetic female mice. J Clin Invest 113 (2004) 85-95
126. Godbout J.P., Pesavento J., Hartman M.E., et al. Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase Cdelta. J Biol Chem 277 (2002) 2554-2561
127. Wurster A.L., Withers D.J., Uchida T., et al. Stat6 and IRS-2 cooperate in interleukin 4 (IL-4)-induced proliferation and differentiation but are dispensable for IL-4-dependent rescue from apoptosis. Mol Cell Biol 22 (2002) 117-126
128. Emanuelli B., Peraldi P., Filloux C., et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276 (2001) 47944-47949
129. Ueki K., Kondo T., and Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24 (2004) 5434-5446
130. Uehara A., Gottschall P.E., Dahl R.R., et al. Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor. Endocrinology 121 (1987) 1580-1582
131. Brown R., Li Z., Vriend C.Y., et al. Suppression of splenic macrophage interleukin-1 secretion following intracerebroventricular injection of interleukin-1 beta: evidence for pituitary-adrenal and sympathetic control. Cell Immunol 132 (1991) 84-93
132. Gaykema R.P., Dijkstra I., and Tilders F.J. Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion. Endocrinology 136 (1995) 4717-4720
133. Pariante C.M., Pearce B.D., Pisell T.L., et al. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 140 (1999) 4359-4366
134. Glezer I., and Rivest S. Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 10 (2004) 538-552
135. Swain M.G., Appleyard C., Wallace J., et al. Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Am J Physiol 276 1 Pt 1 (1999) G199-G205
136. Berczi I., Nagy E., de Toledo S.M., et al. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J Immunol 146 (1991) 2201-2206
137. Goujon E., Parnet P., Laye S., et al. Adrenalectomy enhances pro-inflammatory cytokines gene expression, in the spleen, pituitary and brain of mice in response to lipopolysaccharide. Brain Res Mol Brain Res 36 (1996) 53-62
138. Bertini R., Bianchi M., and Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med 167 (1988) 1708-1712
139. Butler L.D., Layman N.K., Riedl P.E., et al. Neuroendocrine regulation of in vivo cytokine production and effects: I. In vivo regulatory networks involving the neuroendocrine system, interleukin-1 and tumor necrosis factor-alpha. J Neuroimmunol 24 (1989) 143-153
140. Chan O., Inouye K., Riddell M.C., et al. Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol 28 (2003) 87-102
141. Chan O., Inouye K., Akirav E., et al. Insulin alone increases hypothalamo-pituitary-adrenal activity, and diabetes lowers peak stress responses. Endocrinology 146 (2005) 1382-1390
142. Inouye K., Chan O., Riddell M.C., et al. Mechanisms of impaired hypothalamic-pituitary-adrenal (HPA) function in diabetes: reduced counterregulatory responsiveness to hypoglycaemia. Diabetes Nutr Metab 15 (2002) 348-355 [discussion: 355-6, 362]
143. Chan O., Inouye K., Vranic M., et al. Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetes is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity. Endocrinology 143 (2002) 1761-1768